Skip to main content
AMCP Nexus 2023 Main banner

Drugs, Diseases, and the Managed Care Impact

(D4) Navigating NASH: A Discussion on Clinical Background, Patient Advocacy and Managed Care Considerations

Wednesday, October 18, 2023
9:45 AM – 11:00 AM East Coast USA Time
Location: Crystal J2
ACPE UAN:N/A | Contact Hours: N/A | Activity Type: N/A
This session is sponsored by Novo Nordisk, Inc. It is not accredited for continuing pharmacy education credit.

Non-Alcoholic Steatohepatitis (NASH) is an underdiagnosed and underreported hidden and global epidemic affecting more than 115 million people worldwide. An estimated 357 million people will be affected by 2030.

Although no drug is currently FDA-approved for NASH, it is imperative that the medical community, including healthcare professionals, managed care professionals and patients work together to strategize solutions for each phase of the patient’s journey.

This session is designed to increase awareness of NASH among the managed care pharmacy audience. A trio of dynamic speakers, including an expert in the field, a representative from a patient advocacy group, and a managed care pharmacist will discuss the disease, the clinical and economic burden of the disease, access to care, and appropriate treatment.

Learning Objectives::

At the completion of this activity, participants should be able to:
  1. Indicate the pathophysiology, epidemiology, and clinical and economic burdens of NASH to establish urgency in treatment.
  2. Recognize the NASH patient journey including the impact of diagnosis, challenges of access to care, and the importance of the patient involvement continuum.
  3. Discuss managed care benefit design challenges and strategies to optimize access to appropriate treatment.